As of March 31, 2026, the Company maintains the 2023 Equity Incentive Plan (“2023 EIP”). The 2023 EIP reserved 3,614,500 shares of common stock for the grant of various classes of nonqualified stock options, restricted stock units, market condition-based on total shareholder return (“TSR”) and performance condition-based share units (“PSU”) and other forms of equity-based compensation. Shares subject to any awards that expire without being exercised or that are forfeited or settled in cash shall again be available for future grants of awards under the 2023 EIP. Shares subject to stock option or stock appreciation right awards, that have been retained by the Company in payment or satisfaction of the exercise price and any applicable tax withholding obligation of such awards, shall not be available for future grant under the 2023 EIP.

As of March 31, 2026, 2,453,008 shares are available for future grants. The Company’s equity incentive plans are intended to provide an incentive to employees and non-employee directors of the Company to remain in the service of the Company and to increase their interest in the success of the Company in order to promote the long-term interests of the Company. The plans seek to promote the highest level of performance by providing an economic interest in the long-term performance of the Company. The Company settles employee share-based compensation awards with newly issued shares.

During fiscal 2026, the Company granted to management and other key employees 201,989 non-qualified options that vest ratably over 3 years from the date of grant. Options expire 10 years from the date of grant.

The Company recognized stock-based compensation expense relating to stock options of $8,830, with a related tax benefit of $614 for fiscal 2026, $5,869 with a related tax benefit of $1,161 for fiscal 2025 and $7,022 with a related tax benefit of $730 for fiscal 2024.


	Number of Options	Weighted- Average Remaining Contract Term (Years)	Weighted- Average Exercise Price		Aggregate Intrinsic Value
Options outstanding as of March 31, 2023	1,196,311	7.3	$	78.83	$	12,150
Granted	200,314		101.04		—
Exercised	(197,350)		71.81		6,110
Forfeited	(9,166)		78.68		158
Expired	—		—		—
Options outstanding as of March 31, 2024	1,190,109	7.0	$	83.74	$	15,043
Granted	266,027		101.56		—
Exercised	(139,016)		76.66		3,950
Forfeited	(29,340)		98.38		115
Expired	—		—		—
Options outstanding as of March 31, 2025	1,287,780	6.8	$	87.85	$	10,472
Granted	201,989		102.11		—
Exercised	(591,396)		82.55		27,843
Forfeited	(22,033)		92.56		572
Expired	—		—		—
Options outstanding as of March 31, 2026	876,340	7.2	$	94.60	$	69,340
Options exercisable as of March 31, 2026	460,510	5.9	$	87.97	$	39,490
Options vested and expected to vest, as of March 31, 2026	856,681	7.2	$	94.43	$	67,926


Range of Exercise Prices	Number of Options	Weighted- Average Remaining Contractual Life (Years)	Weighted- Average Exercise Price
$57.60 - $60.00	72,717	3.3	$	57.75

$70.01 - $80.00	97,206	5.4	$	74.52
$80.01 - $90.00	5,419	1.1	$	83.14
$90.01 - $100.00	197,925	7.8	$	94.33
$100.01 - $109.69	503,073	7.9	$	104.03
	876,340	7.2	$	94.60

In fiscal 2026, the Company granted to non-employee directors 19,742 deferred restricted stock units (“DSU”) at the fair value of $79.01 per unit at the date of grant. In fiscal 2025, such grants amounted to 19,214 DSU's at the fair value of $76.52 per unit at the date of grant and in fiscal 2024, such grants amounted to 21,147 DSU's units at the fair value of $76.83 unit at the date of grant. The awards vest immediately upon the date of grant and are settled in shares of common stock six months after termination of service as a director.

The Company also granted to non-employee directors, during fiscal 2026, fiscal 2025 and fiscal 2024, 8,047, 9,972, and 8,386 restricted stock units, respectively, at fair values of $113.00, $98.62 and $94.34, respectively, under the deferred compensation plan for non-employee directors.

In fiscal 2026, the Company granted to management and other key employees 327,387 restricted stock units that vest ratably over four years from the date of grant, at the fair value of $95.60 per restricted stock unit.

In fiscal 2025, the Company granted to management and other key employees 361,222 restricted stock units that vest ratably over four years from the date of grant at the fair value of $94.63 per restricted stock unit.

In fiscal 2024, the Company granted to management and other key employees 269,751 restricted stock units that vest ratably over four years from the date of grant at a fair value of $94.31 per restricted stock unit.

A summary of the changes in restricted stock units, including DSU's, and TSRs awarded to employees and directors that were outstanding under the Company’s equity compensation plans during fiscal 2026 is presented below:


	Restricted Stock Units (RSU)			Market condition-based Share Units (TSR)
	Number of RSU	Weighted- Average Grant Date Fair Value		Number of TSR	Weighted- Average Grant Date Fair Value
Non-vested awards as of March 31, 2025	919,707	$	80.42	1,143	$	66.89
Granted	355,176	94.60		—	—
Stock dividend	8,162	82.46		9	66.89
Performance factor	—	—		—	—
Vested	(263,040)	86.87		—	—
Forfeitures	(78,131)	90.76		—	—
Non-vested awards as of March 31, 2026	941,874	$	82.88	1,152	$	66.89

The Company recognized stock-based compensation expense relating to restricted stock units of $28,764, with a related tax benefit of $4,380 for fiscal 2026, $21,867, with a related tax benefit of $3,520 for fiscal 2025 and $23,585, with a related tax benefit of $4,557 for fiscal 2024.

As of March 31, 2026, unrecognized compensation expense associated with the non-vested equity awards outstanding was $64,150 and is expected to be recognized over a weighted-average period of 20 months.